The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called GLP-1.

In this Saturday edition of BI Today, we're talking about the end of a GLP-1 shortage, and Hollywood's awards season.

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...